Form 8-K - Current report:
SEC Accession No. 0001193125-25-055287
Filing Date
2025-03-17
Accepted
2025-03-17 09:15:11
Documents
14
Period of Report
2025-03-14
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K d938957d8k.htm   iXBRL 8-K 32633
  Complete submission text file 0001193125-25-055287.txt   193741

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vnda-20250314.xsd EX-101.SCH 4191
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vnda-20250314_def.xml EX-101.DEF 13768
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20250314_lab.xml EX-101.LAB 22889
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20250314_pre.xml EX-101.PRE 14736
16 EXTRACTED XBRL INSTANCE DOCUMENT d938957d8k_htm.xml XML 5942
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 25742586
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)